Does Elmiron cause Pigmentary Maculopathy?
For years, patients with interstitial cystitis relied on Elmiron (pentosan polysulfate sodium) as the only oral therapy approved for the condition. But starting around 2018, a growing body of evidence began linking long-term use of this drug to a distinctive form of pigmentary maculopathy. As we enter 2026, the question is no longer if Elmiron can cause retinal damage, but how clinicians should manage the risk, monitor patients, and weigh alternatives. We have been tracking this issue since the first major case series emerged, and the regulatory and clinical landscape has shifted dramatically.
The 2018-2022 Case Series That Changed Urology and Retina Practice
The turning point came from a 2018 study by Pearce et al. at Emory University, which described six patients with a peculiar pattern of pigmentary maculopathy after chronic Elmiron use. By 2022, the American Academy of Ophthalmology had issued a warning, and the FDA required label changes. The typical patient profile emerged: women in their 50s and 60s, taking 300-400 mg of Elmiron daily for more than three years, presenting with bilateral, symmetric pigmentary changes in the macula. The condition often progresses even after drug cessation, a fact that continues to alarm retina specialists.
"The risk of pigmentary maculopathy appears to be dose- and duration-dependent. Patients who have taken more than 1,500 grams of pentosan polysulfate sodium over their lifetime are at highest risk." — Based on data from the Emory cohort and subsequent multi-center studies.
Source references: f1000prime.com and archived materials at Web Archive.
We now know that the maculopathy is distinct from age-related macular degeneration. It spares the fovea early on, which explains why many patients retain 20/20 vision until late stages. The classic triad includes: paracentral scotomas, difficulty reading, and photopsias. OCT imaging reveals hyperreflective foci and outer retinal atrophy, while fundus autofluorescence shows a characteristic "bull's eye" pattern of hypoautofluorescence.
2026 Clinical Guidelines: Screening, Monitoring, and the FDA's Stance
The FDA's 2020 safety communication was just the beginning. By 2024, the agency mandated a Risk Evaluation and Mitigation Strategy (REMS) for Elmiron, requiring baseline retinal exams and annual screenings for all patients. In 2026, the conversation has shifted toward earlier detection. We recommend the following protocol based on current consensus from the American Urological Association and the American Society of Retina Specialists:
| Patient Category | Baseline Screening | Follow-Up Interval | Key Imaging |
|---|---|---|---|
| New Elmiron users | Complete eye exam + SD-OCT | Annually after 3 years of use | Fundus autofluorescence, OCT |
| Long-term users (>5 years) | Immediate comprehensive exam | Every 6 months | OCT, FAF, and microperimetry |
| Patients with visual symptoms | Urgent retina referral | Per specialist | Full panel including ERG |
| Post-cessation monitoring | 6-month post-stop exam | Annually for at least 5 years | OCT and FAF to detect progression |
The data shows that progression occurs in up to 40% of patients after stopping Elmiron, with some experiencing worsening over 3-5 years. This has led to a fundamental shift in how we counsel patients: we now emphasize that the drug may cause irreversible damage even after discontinuation.
Alternatives to Elmiron in 2026: What Interstitial Cystitis Patients Need to Know
The litigation landscape has also matured. As of early 2026, over 2,000 Elmiron lawsuits have been filed in U.S. federal courts, with multidistrict litigation (MDL 2973) in New Jersey overseeing bellwether trials. Several cases have resulted in settlements, though Johnson & Johnson (which acquired the drug through its Janssen division) continues to deny causation. For patients, the practical question remains: what can replace Elmiron?
We have seen a surge in interest in alternative therapies. Here are the most viable options as of 2026:
- Intravesical therapy: DMSO (dimethyl sulfoxide) remains FDA-approved for IC, though it requires catheterization. Newer formulations of lidocaine and heparin cocktails are gaining traction.
- Oral therapies: Amitriptyline, hydroxyzine, and cimetidine are used off-label with varying success. No oral drug has matched Elmiron's efficacy, but the risk-benefit ratio now favors alternatives.
- Neuromodulation: Sacral nerve stimulation (InterStim) and percutaneous tibial nerve stimulation (PTNS) are increasingly covered by insurers for IC-related pain.
- Dietary and behavioral modifications: The IC diet (avoiding acidic foods, caffeine, and alcohol) combined with pelvic floor physical therapy remains the first-line non-pharmacologic approach.
- Emerging biologics: Platelet-rich plasma (PRP) injections into the bladder wall are in clinical trials, with early data showing promise for reducing inflammation.
The bottom line for 2026: Elmiron should be reserved for patients who have failed all other therapies and who understand the retinal risks. Baseline and annual eye exams are non-negotiable. For the thousands of patients already exposed, we recommend joining the patient registry at the Emory Eye Center to help refine our understanding of this devastating side effect. The science is settled: Elmiron can cause pigmentary maculopathy, and the medical community must act accordingly.